| Dr Naomi Mattera Nardi, DO | |
|
700 Lilly Rd Ne, Olympia, WA 98506-5115 | |
| (360) 923-7000 | |
| Not Available |
| Full Name | Dr Naomi Mattera Nardi |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 700 Lilly Rd Ne, Olympia, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437589108 | NPI | - | NPPES |
| 036144344 | Medicaid | IL | |
| 1437589108 | Medicaid | WI |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Washington Emergency Physicians Pllc | 0749514735 | 73 |
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 5 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 5 days ago
| Entity Name | Olympia Emergency Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346267796 PECOS PAC ID: 9335035633 Enrollment ID: O20040224000907 |
News Archive
"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 5 days ago
| Entity Name | Thurston Emergency Group A Professional Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558526756 PECOS PAC ID: 4688740517 Enrollment ID: O20080829000199 |
News Archive
"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 5 days ago
| Entity Name | Western Washington Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801352505 PECOS PAC ID: 0749514735 Enrollment ID: O20190625002379 |
News Archive
"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Naomi Mattera Nardi, DO 700 Lilly Rd Ne, Olympia, WA 98506-5115 Ph: (360) 923-7000 | Dr Naomi Mattera Nardi, DO 700 Lilly Rd Ne, Olympia, WA 98506-5115 Ph: (360) 923-7000 |
News Archive
"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Prescription painkillers are responsible for more fatal overdoses in the United States than heroin and cocaine combined. And while most states have programs to curb abuse and addiction, a new report from Brandeis University shows that many states do not fully analyze the data they collect.
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
› Verified 5 days ago
Dr. Jeffrey Howard, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 413 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-491-9480 | |
Dr. Penelope Anne Goode, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 413 Lilly Rd Ne, Olympia Emergency Services, Olympia, WA 98506 Phone: 360-493-4554 | |
Susan A Derry, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 413 Lilly Rd Ne, Msddh09, Olympia, WA 98506 Phone: 360-918-0119 | |
Dr. Lien Hong Ly, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 | |
Dr. Bruce Lincoln, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 413 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-491-9480 | |
Daniel Gilday, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 413 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-493-4400 | |
Dr. Joshua James Sahara, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7318 Grayhawk Ln Ne, Olympia, WA 98516 Phone: 914-217-4372 |